Results 21 to 30 of about 969,782 (213)

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells

open access: yesFrontiers in Oncology, 2022
While PARP inhibitor (PARPi) therapies have shown promising results in the treatment of high-grade serous ovarian cancer (HGSOC) harboring homologous recombination deficiencies, primary resistance to PARPi frequently occurs and even initial responders ...
Yaxun Jia   +6 more
doaj   +1 more source

Long non-coding RNAs in cutaneous melanoma : clinical perspectives [PDF]

open access: yes, 2017
Metastatic melanoma of the skin has a high mortality despite the recent introduction of targeted therapy and immunotherapy. Long non-coding RNAs (lncRNAs) are defined as transcripts of more than 200 nucleotides in length that lack protein-coding ...
Brochez, Lieve   +4 more
core   +1 more source

Unique Molecular Features in High-Risk Histology Endometrial Cancers [PDF]

open access: yes, 2019
Endometrial cancer is the most common gynecologic malignancy in the United States and the sixth most common cancer in women worldwide. Fortunately, most women who develop endometrial cancer have low-grade early-stage endometrioid carcinomas, and simple ...
Collins, Kaitlyn   +4 more
core   +1 more source

A simplified genomic profiling approach predicts outcome in metastatic colorectal cancer [PDF]

open access: yes, 2019
The response of metastatic colorectal cancer (mCRC) to the first-line conventional combination therapy is highly variable, reflecting the elevated heterogeneity of the disease.
Belardinilli, Francesca   +29 more
core   +2 more sources

Management of imatinib-resistant CML patients [PDF]

open access: yes, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Branford S   +21 more
core   +1 more source

Molecular imaging and targeted therapies [PDF]

open access: yesBiochemical Pharmacology, 2010
Targeted therapeutic and imaging agents are becoming more prevalent, and are used to treat increasingly smaller segments of the patient population. This has lead to dramatic increases in the costs for clinical trials. Biomarkers have great potential to reduce the numbers of patients needed to test novel targeted agents by predicting or identifying non ...
David L, Morse, Robert J, Gillies
openaire   +2 more sources

Major roles of the circadian clock in cancer

open access: yesCancer Biology & Medicine, 2023
Circadian rhythms are natural rhythms that widely exist in all creatures, and regulate the processes and physiological functions of various biochemical reactions. The circadian clock is critical for cancer occurrence and progression.
Chen Huang   +4 more
doaj   +1 more source

Breast cancer as photodynamic therapy target: Enhanced therapeutic efficiency by overview of tumor complexity [PDF]

open access: yes, 2014
Photodynamic therapy is a minimally invasive and clinically approved procedure for eliminating selected malignant cells with specific light activation of a photosensitizer agent.
Lamberti, María Julia   +2 more
core   +1 more source

Molecular Targets for AIDS Therapy [PDF]

open access: yesScience, 1990
The development of antiretroviral therapy against acquired immunodeficiency syndrome (AIDS) has been an intense research effort since the discovery of the causative agent, human immunodeficiency virus (HIV). A large array of drugs and biologic substances can inhibit HIV replication in vitro.
H, Mitsuya, R, Yarchoan, S, Broder
openaire   +2 more sources

Menin–MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers

open access: yesMolecules, 2023
Encoded by the MEN1 gene, menin protein is a fusion protein that is essential for the oncogenic transformation of mixed-lineage leukemia (MLL) and leads to acute leukemia (AL). Therefore, accumulating evidence has demonstrated that inhibition of the high-
Qing Shi   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy